A PHASE 1/2, RANDOMIZED, DOUBLE-BLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER
Latest Information Update: 18 Jun 2026
At a glance
- Drugs Pneumococcal 20-valent conjugate vaccine (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 10 Jun 2026 Status changed from active, no longer recruiting to completed.
- 14 Oct 2025 Planned End Date changed from 13 Aug 2025 to 23 May 2026.
- 14 Oct 2025 Planned primary completion date changed from 13 Aug 2025 to 23 May 2026.